You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magneti
SBC: Theragnostic Technologies Inc. Topic: NIDDKAbstract This STTR phase 1 proposal investigates the safety and efficacy of a novel high-performance carbon nanostructure-based magnetic resonance imaging (MRI) contrast agent for the imaging and monitoring of patients with renal failure. Every year, in the US, approximately 20 million people are treated for mild to severe renal failure. A significant number of cases (greater than 50%) related to ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
In-situ, real-time oxygen sensor to monitor the long-term efficacy of aerobicall
SBC: ChromoSense LLC Topic: NIEHSDESCRIPTION (provided by applicant): Groundwater and soil contamination has been associated with higher incidence of birth defects and cancer. Monitored natural attenuation of contaminants via biodegradation has proven effective in lowering contaminant levels, but these processes depend critically on dissolved oxygen levels. This project proposes to develop a robust oxygen sensor compound with che ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Zonular Capture Accommodative-Disaccommodative Intraocular Lens System
SBC: Z Lens LLC Topic: NEIDESCRIPTION (provided by applicant): We are developing an accommodative - disaccommodative intraocular lens implant (ADIOL) system based on a novel concept of capturing zonular tension and transmitting it unimpeded to a dynamically position intraocular lens system. This is made possible by a zonular capture haptic (ZCH) apparatus. This apparatus lends itself equally well to several possible combin ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
The Retroject Device: A Novel Approach to Glaucoma Drug Delivery
SBC: RETROJECT, INC. Topic: NEIPROJECT ABSTRACT Glaucoma is a common neurodegenerative disease which is the 2nd leading cause of blindness in the United States. With the aging baby boomer population, these numbers will continue to increase exponentially over the next few decades. With glaucomatous progression, there is ultimately damage to the optic nerve which results in peripheral vision loss. It has been shown in many prior ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Topical Therapeutic to Promote Healing of Chronic Wounds
SBC: Phoenicia Biosciences, Inc. Topic: NIGMSDESCRIPTION (provided by applicant): Chronic refractory, or non-healing, wounds or ulcerations of the extremities represent a major medical condition affecting millions of patients. A chronic wound is defined as a wound that does not show signs of significant healing, or progresses, after use of topical/surgical treatment measures for six months. Non-healing wounds affect 6.5 million patients, aff ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
human Microvessel Culture System (hMCS)
SBC: ANGIOMICS, INC. Topic: NHLBIDESCRIPTION (provided by applicant): Human Microvessel Culture System (hMCS) Angiogenesis-targeting therapies, either inhibiting or promoting new vessel growth, have the potential for treating numerous diseases including cancer, eye diseases, cardiac and peripheral vascular disease, skin disorders, fibro-proliferative diseases, and inflammatory conditions such as arthritis. Furthermore, growing ev ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Selective HDAC1/2 inhibitors for hemoglobinopathies
SBC: ACETYLON PHARMACEUTICALS, INC. Topic: NHLBIDESCRIPTION (provided by applicant): The long term goal of this project is a selective Histone Deacetylase 1 and 2 (HDAC1/2) inhibitor for the treatment of patients with the beta-hemoglobinopathies sickle cell anemia and beta- thalassemia. An estimated 400,000 children are born each year with one of these hemoglobin disorders. Few treatments exist to alleviate the symptoms of hemoglobinopathies an ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Innovative Use of the Noom Monitor Mobile Application for CBT-GSH in Binge Eaters
SBC: Noom, Inc. Topic: NIMHDESCRIPTION (provided by applicant): Bulimia nervosa and binge eating disorder are marked by significant levels of impairment and psychiatric comorbidity, affecting approximately 5-7% of the US population. Guided self-help cognitive behavioral (CBT-GSH) therapy has been show to be an effective treatment to reduce binge eating for patient with both disorders. However, there is limited uptake among ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Remote focusing through spatial light modulation for multifocal multiphoton micro
SBC: BOULDER NONLINEAR SYSTEMS, INC. Topic: NIMHDESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Neurorestorative therapy of stroke with HUCBC in T2DM rats
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health